JMDSJournal of Medicines Development Sciences2382-63632382-6371WHIOCE PUBLISHING PTE. LTD.10.18063/jmds.v1i1.107Review ArticlePhilanthropies as partners for drug development in  public–private partnershipshttps://artdesignp.com/journal/JMDS/1/1/10.18063/jmds.v1i1.107D. LimMark,A. BrumfieldMartha,GoldmanMichel2015112015-06-12Disease-focused philanthropic organizations play an increasing role in the strategy and conduct of biomedical  research, with many focusing on drug development for specific diseases and patient populations. More and more they  not only provide resources and expertise, but also take active part managing the strategy and objectives of targeted research programs, using approaches such as venture philanthropy. Many also lead and participate in public–private partnerships. One example is the partnership between the Polycystic Kidney Disease (PKD) Foundation and the Critical  Path Institute (C-Path) which brings together several pharmaceutical companies and academic institutions to develop  new broadly-used biomarkers. Another case is the partnership between JDRF (formerly known as the Juvenile Diabetes  Research Foundation) and the Innovative Medicines Initiative (IMI), involving financial support of the IMIDIA project  (Innovative Medicines Initiative for Diabetes) which is focused on improving beta-cell function and identifying biomarkers for diabetes treatment monitoring. These examples show that in addition to providing financial support and  expertise, philanthropic foundations are also in a unique position to coordinate the patient and research communities to  enable and accelerate specific medicines development projects.Philanthropic foundation, venture philanthropy, polycystic kidney disease, type 1 diabetes

1. Lim, M. D. (2014). Consortium sandbox: building and sharing resources. Science Translational Medicine, vol.6: 242cm6. http://dx.doi.org/10.1126/scitranslmed.3009024.2. Cain, C. (2012). A mind for precompetitive collaboration. Science-Business eXchange, vol.5(19). http://dx.doi.org/10.1038/scibx.2012.483.3. Evaluate Pharma World Preview 2014, Outlook to 2020. Viewed on March 20, 2015, <http://www.evaluategroup.com/Public/Reports/EvaluatePharma-World-Preview-2014.aspx>4. Berkley, S. (2015). Share the risks of Ebola vaccine development. Nature, vol.519(7543): 263. http://dx.doi.org 10.1038/519263a.5. Partnerships key for future development agenda. Viewed on March 20, 2015, <http://www.un.org/apps/news/story.asp?NewsID=50074 - .VRdh0I10xbX>6. Joanette, Y., Hirsch, E. C., & Goldman, M. (2014). The global fight against dementia. Science Translational Medicine, vol.6(267): 267ed22. http://dx.doi.org/10.1126/scitranslmed.aaa4486.7. BNP paribas individual philanthropy index 2015. Viewed on March 20, 2015, <http://www.wealthmanagement.bnpparibas.com/public/en/achieving-your-goals-index-2015>8. Jarvis, L. M. (2012). Advancing R&D by venture philanthropy. Chemical & Engineering News, vol.90(45): 14−18.9. TRAIN Central Station. Viewed on May 5, 2015, <http://train.fastercures.org/>10. Feldman, M. P., & Graddy-Reed, A. (2014). Accelerating commercialization: a new model of strategic foundation funding. The Journal of Technology Transfer, vol.39(4): 503−523. http://dx.doi.org/10.1007/s10961-013-9311-1.11. PKD Foundation. Viewed on May 4, 2015, <http://www.pkdcure.org/>12. Critical Path Institute. Viewed on May 5, 2015, <http://c-path.org/programs/pkd/>